Zurcher Kantonalbank (Zurich Cantonalbank) Immunovant, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Immunovant, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 7,925 shares of IMVT stock, worth $218,016. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,925

Previous 7,925 -0.0%

Holding current value

$218,016

Previous $218,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$25.1 - $31.61 $125 - $158	-5 Reduced 0.06%	7,925 $209,000
Q1 2024 Apr 25, 2024	SELL	$30.27 - $43.79 $73,858 - $106,847	-2,440 Reduced 23.53%	7,930 $256,000
Q4 2023 Jan 30, 2024	BUY	$31.31 - $44.19 $29,775 - $42,024	951 Added 10.1%	10,370 $436,000
Q3 2023 Oct 25, 2023	SELL	$18.55 - $39.96 $5,212 - $11,228	-281 Reduced 2.9%	9,419 $361,000
Q2 2023 Aug 07, 2023	BUY	$14.2 - $23.75 $53,676 - $89,775	3,780 Added 63.85%	9,700 $184,000
Q1 2023 May 08, 2023	SELL	$15.27 - $19.72 $20,950 - $27,055	-1,372 Reduced 18.82%	5,920 $91,000
Q4 2022 Feb 01, 2023	SELL	$6.59 - $17.75 $5,166 - $13,916	-784 Reduced 9.71%	7,292 $129,000
Q1 2022 Apr 21, 2022	BUY	$5.06 - $8.77 $12,371 - $21,442	2,445 Added 43.42%	8,076 $44,000
Q4 2021 Feb 01, 2022	SELL	$7.33 - $9.32 $879 - $1,118	-120 Reduced 2.09%	5,631 $48,000
Q3 2021 Nov 15, 2021	SELL	$7.01 - $11.37 $42 - $68	-6 Reduced 0.1%	5,751 $50,000
Q2 2021 Jul 30, 2021	BUY	$9.4 - $16.85 $488 - $876	52 Added 0.91%	5,757 $61,000
Q1 2021 May 03, 2021	BUY	$13.08 - $49.6 $15,970 - $60,561	1,221 Added 27.23%	5,705 $92,000
Q4 2020 Jan 28, 2021	BUY	$36.36 - $52.71 $33,742 - $48,914	928 Added 26.1%	4,484 $207,000
Q3 2020 Nov 06, 2020	BUY	$22.61 - $38.9 $80,401 - $138,328	3,556 New	3,556 $125,000

Others Institutions Holding IMVT

# of Institutions

211

Shares Held

66.9M

Call Options Held

2.3M

Put Options Held

631K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account

Zurcher Kantonalbank (Zurich Cantonalbank) Immunovant, Inc. Transaction History